OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
- OPKO Health made significant progress in ModeX's antiviral and immune-oncology pipeline, securing collaborations with Merck and BARDA for novel therapies.
- NGENLA received approvals in over 50 countries, with Pfizer launching the product globally. OPKO is entitled to gross profit sharing in all markets.
- BioReference Health continued its REACH program to enhance productivity and achieve profitability, expanding into new markets and customer segments.
- Revenue from pharmaceutical products increased in the fourth quarter of 2023, driven by international sales growth and intellectual property transfers.
- However, total costs and expenses rose primarily due to higher product revenue costs and increased research and development expenses.
- Diagnostics revenue decreased in the fourth quarter, attributed to lower clinical test reimbursement and COVID-19 testing volume declines.
- Consolidated total revenues slightly decreased, while operating losses widened in the fourth quarter of 2023.
- OPKO completed a significant convertible notes offering post-quarter-end, utilizing the proceeds for share repurchases and debt exchanges.
- Operating losses widened in both the pharmaceuticals and diagnostics segments in the fourth quarter of 2023.
- Diagnostics revenue declined due to lower clinical test reimbursement and reduced COVID-19 testing volume.
- Consolidated total revenues slightly decreased, impacting the company's financial performance in the fourth quarter of 2023.
Insights
The reported increase in pharmaceutical revenue, particularly from international operations, is a positive indicator of OPKO Health's market expansion and the successful penetration of its products globally. The growth in sales and the favorable impact from foreign currency fluctuations suggest a robust demand for OPKO's pharmaceutical offerings, which can be a key driver for future revenue growth. However, the reported operating loss, despite being lower than the previous year, raises concerns about the company's current profitability. The strategic move to issue convertible notes and manage debt could be viewed as a proactive approach to strengthen the balance sheet, but it also warrants monitoring for its impact on shareholder dilution and future interest obligations.
OPKO Health's entry into the Chinese market through Alibaba's Tmall Global Platform represents a significant strategic initiative, tapping into one of the world's largest consumer markets. The focus on health and wellness products aligns with the growing consumer health consciousness in China. However, the success of this venture will depend on regulatory approvals and the ability to navigate the competitive landscape of e-commerce in China. The diversification into animal health products could also open new revenue streams but requires careful market analysis and an understanding of consumer preferences in the region.
The advancement of ModeX’s antiviral and immune-oncology pipeline, including the collaboration with Merck on a vaccine for Epstein-Barr virus, is an example of OPKO's commitment to innovation in high-potential therapeutic areas. The entry of an oncology program into the clinic could signal a significant milestone for the company, potentially leading to future revenue streams if clinical outcomes are positive. Moreover, the approval of NGENLA in over 50 countries and the gross profit sharing arrangement with Pfizer could have substantial financial implications, contingent on the product's market uptake and competitive landscape.
Conference call begins at 4:30 p.m. Eastern time today
MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
Business highlights from the fourth quarter and subsequent weeks included the following:
- ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies, with expectations for one oncology program to enter the clinic this year. In 2023, Modex secured two collaborations including one with Merck to develop MDX-2201, its vaccine for Epstein-Barr virus, and another with BARDA to develop novel multispecific antibodies against viral infectious disease threats.
- NGENLA® has now been approved in over 50 countries including the U.S., Japan, EU Member States, Canada and Australia. Pfizer, OPKO’s commercial partner, has launched NGENLA in all priority global markets. OPKO is entitled to gross profit sharing in all global markets based on sales of both NGENLA and Genotropin. NGENLA is the first once-weekly product approved for the treatment of pediatric growth hormone deficiency in Japan, Canada, Australia, the United Kingdom, Taiwan, the United Arab Emirates and Brazil.
- BioReference Health continued implementing its REACH program to improve operating efficiencies and enhance productivity. With the goal of achieving profitability this year, BioReference continued to implement initiatives to reduce costs and improve productivity by enhancing innovation of its higher-value specialty testing segments. Other efforts to return this business to profitability include expanding into new markets and marketing to new customer segments, such as pharmaceutical companies.
- Approvals received for OPKO Health-branded Storefront on Alibaba’s Tmall Global Platform in China. NextPlat Corp., a global e-Commerce provider, is launching an OPKO Health-branded online storefront on Alibaba's Tmall Global e-commerce platform in China. This new online storefront will initially list up to 40 OPKO health and wellness products featuring an assortment of nutraceuticals for bone, joint and eye health, as well as supplements for nutrition and immunity defense. NextPlat intends to significantly expand the OPKO online storefront with a wide array of veterinary and animal health products, subject to final Chinese regulatory approval, which is expected during the second quarter of 2024.
Fourth Quarter Financial Results
- Pharmaceuticals: Revenue from products in the fourth quarter of 2023 increased to
$43.0 million from$37.9 million in the fourth quarter of 2022, driven by growing sales from our international operations, positively impacted by foreign currency fluctuations of approximately$1.3 million . Furthermore, sales of RAYALDEE increased to$9.3 million from$9.1 million in the prior-year period. Revenue from the transfer of intellectual property was$14.7 million in the fourth quarter of 2023 compared with$8.1 million in the 2022 period, which included revenue of$12.2 million and$3.0 million , respectively, of gross profit share payments for NGENLA; the fourth quarter of 2023 included a catch-up payment of$3.1 million for the U.S. for the third quarter of 2023. Total costs and expenses were$73.8 million in the fourth quarter of 2023 compared with$68.0 million in the prior-year period. The increase was primarily from higher cost of product revenues reflecting sales growth from OPKO’s international operating companies, negatively impacted by unfavorable foreign currency fluctuations of$1.1 million . Furthermore, research and development expenses increased as we continued to invest in our pipeline of immune-oncology and infectious disease programs. Operating loss was$16.0 million in the fourth quarter of 2023 compared with$22.0 million in the fourth quarter of 2022. - Diagnostics: Revenue from services in the fourth quarter of 2023 was
$124.2 million compared with$139.4 million in the prior-year period. The decrease reflects lower clinical test reimbursement of$9.0 million due to the mix of testing ordered, partially offset by an increase of$0.9 million from higher clinical test volume. COVID-19 testing volume and reimbursement decreased by$7.1 million due to higher utilization of antigen point-of-care diagnostic tests, as well as a shift in customer mix. Total costs and expenses for the fourth quarter of 2023 were$166.4 million compared with$162.5 million in the fourth quarter of 2022. This increase is primarily due to non-recurring employee retention and severance costs associated with our ongoing REACH initiatives. Through these initiatives, the Company has reduced ongoing expenses on an annualized basis by$10.1 million . Operating loss in the fourth quarter of 2023 was$42.3 million , including$4.7 million of non-recurring expenses and$5.4 million of revenue adjustments, compared with an operating loss of$23.1 million in the 2022 period. - Consolidated: Consolidated total revenues for the fourth quarter of 2023 were
$181.9 million compared with$185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was$69.1 million compared with an operating loss of$55.3 million for the 2022 quarter. Net loss for the fourth quarter of 2023 was$65.5 million , or$0.09 per share, compared with a net loss of$85.2 million , or$0.11 per share, for the 2022 quarter. Net loss for the 2023 period included a mark-to-market adjustment of$3.2 million compared with$49.1 million in the 2022 period related to the decrease in the share price of GeneDx. In addition, OPKO reported an income tax benefit in the 2023 period of$6.0 million compared with$17.0 million in the 2022 period. - Cash and cash equivalents: Cash and cash equivalents were
$95.9 million as of December 31, 2023. Subsequent to the close of the fourth quarter, OPKO completed the sale of$230 million aggregate principal amount of3.75% Convertible Senior Notes due 2029 and exchanged approximately$144.4 million of the Company’s outstanding4.50% Convertible Senior Notes due 2025. The Company used approximately$50.0 million of the net proceeds to repurchase shares of the Company’s common stock from purchasers of the notes. Additionally, OPKO issued and sold approximately$71.1 million aggregate principal amount of its3.75% Convertible Senior Notes due 2029 to several holders, including Company affiliates in exchange for the outstanding5% Convertible Promissory Notes and accrued interest.
Conference Call and Webcast Information
OPKO’s senior management will provide a business update, discuss fourth quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until March 5, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6034226. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether our products will launch in all the territories in which they have been approved for sale, the timing of such launches, our product development efforts and the expected benefits of our products, whether the relationship with our commercial and strategic partners will be successful, whether our commercial and strategic partners will be able to commercialize our products and successfully utilize our technologies, our ability to market and sell any of our products in development, whether we will continue to successfully advance products in our pipeline and whether they can be commercialized, our expectations about RAYALDEE, whether BioReference’s cost-cutting initiatives and attempts at returning to its core business will be successful, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
—Tables to Follow—
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in millions) Unaudited | |||||||
| As of | |||||||
| December 31, 2023 | December 31, 2022 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 95.9 | $ | 153.2 | |||
| Other current assets | 213.6 | 241.3 | |||||
| Total current assets | 309.5 | 394.5 | |||||
| In-process research and development and goodwill | 793.3 | 790.9 | |||||
| Other assets | 908.9 | 981.9 | |||||
| Total Assets | $ | 2,011.7 | $ | 2,167.3 | |||
| Liabilities and Equity: | |||||||
| Accounts payable | $ | 69.7 | $ | 67.0 | |||
| Accrued expenses | 90.1 | 98.3 | |||||
| Current portion of convertible notes | 0.0 | 3.1 | |||||
| Other current liabilities | 40.3 | 45.1 | |||||
| Total current liabilities | 200.1 | 213.5 | |||||
| Long-term portion of convertible notes | 214.3 | 210.4 | |||||
| Deferred tax liabilities, net | 126.8 | 126.4 | |||||
| Other long-term liabilities, principally contract liabilities, leases, contingent consideration, and lines of credit | 81.3 | 55.4 | |||||
| Total Liabilities | 622.5 | 605.7 | |||||
| Equity | 1,389.2 | 1,561.6 | |||||
| Total Liabilities and Equity | $ | 2,011.7 | $ | 2,167.3 | |||
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in millions, except share and per share data) Unaudited | |||||||||||||||
| For the three months ended December 31, | For the twelve months ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues | |||||||||||||||
| Revenue from services | $ | 124.2 | $ | 139.4 | $ | 515.3 | $ | 755.6 | |||||||
| Revenue from products | 43.0 | 37.9 | 167.5 | 142.9 | |||||||||||
| Revenue from transfer of intellectual property and other | 14.7 | 8.1 | 180.7 | 105.7 | |||||||||||
| Total revenues | 181.9 | 185.4 | 863.5 | 1,004.2 | |||||||||||
| Costs and expenses | |||||||||||||||
| Cost of service revenues | 112.4 | 106.4 | 445.8 | 627.6 | |||||||||||
| Cost of product revenues | 24.8 | 23.0 | 99.5 | 88.4 | |||||||||||
| Selling, general, and administrative | 72.9 | 74.0 | 300.6 | 372.7 | |||||||||||
| Research and development | 19.4 | 19.5 | 89.6 | 73.9 | |||||||||||
| Contingent consideration | (0.0 | ) | (0.6 | ) | (1.0 | ) | (1.3 | ) | |||||||
| Amortization of intangible assets | 21.5 | 21.6 | 86.0 | 87.8 | |||||||||||
| Gain on sale of assets | 0.0 | (3.2 | ) | 0.0 | (18.6 | ) | |||||||||
| Total costs and expenses | 251.0 | 240.7 | 1,020.5 | 1,230.5 | |||||||||||
| Operating loss | (69.1 | ) | (55.3 | ) | (157.0 | ) | (226.3 | ) | |||||||
| Other expense, net | (3.4 | ) | (46.9 | ) | (27.4 | ) | (165.2 | ) | |||||||
| Loss before income taxes and investment losses | (72.5 | ) | (102.2 | ) | (184.4 | ) | (391.5 | ) | |||||||
| Income tax benefit (provision) | 6.0 | 17.0 | (4.4 | ) | 63.5 | ||||||||||
| Loss before investment losses | (66.5 | ) | (85.2 | ) | (188.8 | ) | (328.0 | ) | |||||||
| Loss from investments in investees | (0.0 | ) | (0.0 | ) | (0.1 | ) | (0.4 | ) | |||||||
| Net loss | $ | (65.5 | ) | $ | (85.2 | ) | $ | (188.9 | ) | $ | (328.4 | ) | |||
| Loss per share, basic and diluted | $ | (0.09 | ) | $ | (0.11 | ) | $ | (0.25 | ) | $ | (0.46 | ) | |||
| Weighted average common shares outstanding, basic and diluted | 751,506,257 | 750,169,485 | 751,716,915 | 719,060,942 | |||||||||||
FAQ
What were the key business highlights for OPKO Health in the fourth quarter of 2023?
How did revenue from pharmaceutical products perform in the fourth quarter of 2023?
What led to the increase in total costs and expenses for OPKO Health in the fourth quarter of 2023?
What caused the decrease in diagnostics revenue for OPKO Health in the fourth quarter of 2023?
What was OPKO Health's net loss for the fourth quarter of 2023?
What significant financial transaction did OPKO Health complete post-quarter-end?
